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 Signaling through epidermal growth factor receptor (EGFR/ErbB) family 
members plays a very important role in regulating proliferation, development, and 
malignant transformation of mammary epithelial cells.  ErbB family members are often 
over-expressed in human breast carcinomas.   Lapatinib is an ErbB1 and ErbB2 tyrosine 
kinase inhibitor that has been shown to have anti-proliferative effects in breast and lung 
cancer cells.  Cells treated with Lapatinib undergo G1 phase arrest, followed by apoptosis.  
Lapatinib has been approved for clinical use, though patients have developed resistance 
to the drug, as seen previously with other EGFR inhibitors.  Moreover, the therapeutic 
efficacy varies significantly within the patient population, and the mechanism of drug 
sensitivity is not fully understood.  Expression levels of ErbB2 are used as a prognostic 
marker for Lapatinib response; however, even among breast tumor cell lines that express 
similar levels of ErbB2 there is marked difference in their proliferative responses to 
Lapatinib.  
 To understand the mechanisms of acquired resistance, we established a cell line 
SkBr3-R that is resistant to Lapatinib, from a Lapatinib-sensitive breast tumor cell line, 
SkBr3.   We have characterized the cell lines and demonstrated that Lapatinib resistance 
in our system is not facilitated by receptor-level activity or by previously known 
mutations in the ErbB receptors.  Significant changes were observed in cell proliferation, 
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cell migration, cell cycle and cell death between the Lapatinib resistant SkBr3-R and 
sensitive SkBr3 cell lines.  Recent studies have suggested STAT3 is upregulated in 
Lapatinib resistant tumors in association with ErbB signaling.  We investigated the role 
that STAT3 may play in Lapatinib resistance and discovered higher STAT3 activity in 
these resistant cells.  In addition, transcriptional profiling indicated higher expression of 
STAT3 target genes, as well as of other genes that promote survival.  The gene array data 
also revealed cell cycle regulators and cell adhesion/junction component genes as 
possible mediator of Lapatinib resistance.  Altogether, this study has identified several 
possible mechanisms of Lapatinib resistance. 
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CHAPTER 1:  INTRODUCTION AND LITERATURE REVIEW 
 
Understanding the acquired resistance of breast tumor cells to pharmacological 
agents remains an open and challenging area of research.  This report investigates the 
acquired resistance from prolonged treatment of Lapatinib in a breast tumor cell line.  
The background provided here covers breast cancer, advances in the field, specifically in 
the area of targeted therapy, the drug Lapatinib and its targets, and previous studies in 
drug resistance.  Additionally, a review of the literature on STAT3 and its link to ErbB 
signaling and drug resistance will be discussed.  Finally, the specific aims of this project 
will be discussed. 
 
BREAST CANCER 
Worldwide, breast cancer is the leading cause of death from cancer in women (3).  
It is the second most common cause of cancer death among women in the US, following 
lung cancer.  In 2009, the American Cancer Society estimated that 192,370 new cases of 
invasive breast cancer would be diagnosed among women in the United States, and over 
40,170 deaths by year’s end (4).  Historically, incident rates increased in the 1980s and 
mid 1990s, afterwhich it reached a plateau, when the use of mammography screening was 
increased.  Between 1999 and 2006 incident rates dropped 2.0% annually (4), likely due 
to decreased use of menopausal hormones as well as increase in mammography 
screening. 
The breast anatomy includes the glands (lobules), the ducts (small tubes that 
connect the lobules to the nipple), fatty and connective tissue, blood vessels, and lymph 
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vessels.  Milk is produced by the glands and carried to the nipple through the ducts.  The 
connective tissue holds everything together.  Breast cancer can be classified based on 
tissue of origin:  lobular and ductal.   Both type of carcinoma can be classified into two 
subgroup based whether cancer cells are in situ or invasive.   Invasive carcinoma 
accounts for about 80 percent of breast cancer (5).   
 Breast cancer, like many other forms of cancer, is believed to be caused by both 
environmental and hereditary factors.  Exposure to chemicals, viruses, or radiation can 
cause DNA damage that leads to genetic mutations (6).  Another risk factor is the failure 
of early stage immune surveillance system (7).  Abnormal growth factor signaling in the 
cells has also been linked to tumor expansion (2).  Inherited defects in DNA repair genes, 
such as BRCA1, BRCA2, PTEN and TP53, can also contribute to breast cancer 
development (8). 
 
ADVANCES AND THERAPIES 
Over the past decades there have been many advancements in the areas of 
prevention, diagnosis, and treatment of breast cancer.  Today, nearly 90% of patients who 
have been diagnosed with breast cancer will survive at least five years (9).  Mastectomy 
alone is no longer the only accepted surgical option for treatment.  Lumpectomy, 
followed by radiation therapy has replaced mastectomy as the preferred approach for 
women with early stage breast cancer (10).  Mammographic screening has reduced 
mortality (11).  It is now routinely utilized as an accepted standard for early detection.  
Combinational chemotherapy has become standard in the adjuvant treatment of patients 
in early stage of cancer.  The use of chemotherapy is to help reduce metastatic tumors.  
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Clinical trials are currently underway using neoadjuvant chemotherapy, which is a 
treatment given before surgery to shrink tumor mass.  Hormonal therapy with selective 
estrogen receptor modulators (SERMs) such as tamoxifen, and aromatase inhibitors is 
also standardized in the treatment of women with estrogen receptor (ER) positive breast 
cancer.  SERMs prevents estrogen from binding to its receptor, thus preventing growth 
stimulation by estrogen (11).  In contrast, aromatase inhibitors block estrogen production 
(11).  Some Food and Drug Administration (FDA) approved aromatase inhibitors include 
anastrozole, exemestane, and letrozole.  The use of hormonal therapy has been adapted 
for both early stage and advanced stage of cancer.  Tamoxifen and another SERM, 
raloxifene, have been shown to prevent the development of invasive breast cancer.  
Hence, tamoxifen has been an effective treatment option as well as prevention strategy. 
Her2 (human epidermal growth factor receptor 2), also known as ErbB2, is 
overexpressed in about 20% of breast cancer, and therapies targeting activity of this 
protein are being investigated (12-14).  Monoclonal antibodies and small-molecule 
tyrosine kinase inhibitors are currently in clinical use for the advanced and metastatic 
ErbB2 positive breast cancer patients.  For the next few sections of this chapter, we will 
focus on the role of ErbB2 protein in cancer. 
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ERBB RECEPTORS 
ErbB2 is a member of the epidermal growth factor receptor family of tyrosine 
kinases [ErbB1/EGFR, ErbB2/Her2/Neu, ErbB3, and ErbB4] that regulate cell growth, 
survival, migration, adhesion, proliferation and differentiation (15-17).   Members of this 
family have an extracellular ligand binding region, single membrane spanning region, 
and a cytoplasmic tyrosine kinase containing domain.  The epidermal growth factor 
(EGF) family of growth factors serve as ligands for the ErbB receptors and is divided into 
three groups based on the receptors they bind.  The first group includes EGF, 
transforming growth factor (TGFα), amphiregulin (AR), and epigen (EPG); this group 
binds to EGFR.  The second group binds to EGFR and ErbB4, and includes beta-cellulin 
(BTC), heparin-binding EGF (HB-EGF) , and epiregulin (EPR).  The third group is 
further divided into two subgroups of neuregulins (NRGs):  1) NRG1 and NRG2 which 
are specific for ErbB3 and ErbB4, and 2) NRG3 and NRG4 which are specific for ErbB4 
only (18).  
Following ligand binding, an ErbB receptor homodimerizes or heterodimerizes 
with another ErbB family member, followed by autophosphorylation of specific tyrosine 
residues in the intrinsic kinase domain (2).  See Figure 1.  The known combinations of 
dimerization are shown in Figure 1A where ErbB1, ErbB3, and ErbB4 can all form 
homodimers or heterodimers with ErbB2.  ErbB2 lacks the extracellular binding domain 
and therefore does not bind to a ligand; it can however dimerize and activate itself and is 
a preferred partner for heterodimerization with the other ErbB receptors (Hynes and Lane 
2005). 
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 The phosphorylation sites serve as docking sites for recruitment of proteins that 
lead to activation of intracellular signaling pathways.  Several different signaling 
pathways may be activated depending on which specific receptor residues phosphorylated 
and the proteins recruited, as shown in Figure 1B.  For example, the mitogen-activated 
protein kinase (MAPK) cascade that affect growth, differentiation and apoptosis is 
activated by recruitment of growth-factor-receptor-bound protein 2 (GRB2) and Src 
homology 2 domain-containing (SHC) protein to the receptor.  The recruitment of GRB2 
is dependent on the phosphorylation on EGFR at residues 1068/1086 and 1173 and on 
ErbB2 at residues 1139 while SHC recruitment depends on ErbB2 phosphorylation at 
121/122.  Another important pathway, the phosphatidylinositol 3-kinase (PI3K)−AKT, 
which mediates anti-apoptotic activities, is stimulated through recruitment of the p85 
adaptor subunit of PI3K to the ErbB3 receptor (2).  Other pathways, such as those 
containing effectors like SRC tyrosine kinase, mammalian target of rapamycin (mTOR), 
are also activated as a result of EGFR activation (2).  Alternative signaling cascades, such 
as those of the signal transducer and activator of transcription (STAT) family, leads to 
activation of transcription factors; for example STAT3, which translocates to the nucleus 
and activate pro-survival factors (2).  
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Figure 1. Ligands that bind known dimerizations and phosphorylation sites of the 
ErbB family of receptors.  
A) Different homo and hetero dimers that can be formed by the ErbB receptors, 
along with ligands that can bind and activate the corresponding dimers.  B) The 
phosphorylation sites in the kinase domain of the ErbB receptors and the 
intracellular signaling proteins that are recruited to the corresponding sites.  
Reprinted by permission from Macmillan Publishers Ltd:  Nature Review Cancer 
(2), copyright 2005. 
A 
B 
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 ERBB1 AND ERBB2 IN CANCER 
Many studies have shown that EGFR and ErbB2 have been associated with a 
variety of characteristics of cancer, such as increased proliferation, decreased apoptosis, 
metastasis, and resistance to chemotherapy and radiotherapy (19, 20).  In addition, EGFR 
and ErbB2 have been reported to be amplified, overexpressed, or mutated in numerous 
solid tumor types, including 20-30% of breast cancers where they are linked to aggressive 
cancer category and poor patient outcome (12-14).  For example, in gliomas EGFR 
amplification was found concomitantly with mutations in the extracellular domain of type 
3 variant of EGFR (21).  Furthermore, many EGF-related growth factors are produced 
either by the tumor cells themselves or the surrounding stomal cells, causing constitutive 
activation of EGFR (22, 23).   
The ErbB2 gene has also been reported to be amplified in human breast cancer 
(24), and its overexpression by transfection methods results in transformation of normal 
human fibroblasts (25).  In nude mice, ErbB2 amplified breast cancer cells exhibit higher 
rates of DNA synthesis, proliferation, invasion and metastatic potential (26, 27).  It has 
been demonstrated that ErbB2 transgenic mice develop breast cancer (28).  ErbB2 
overexpression has shown to increase the outgrowth of metastatic tumor cells in the 
brain. 
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ERBB TARGETED THERAPEUTICS 
The established role of EGFR and ErbB2 in promoting growth and survival of 
various tumor types make them attractive therapeutic targets.  Drugs that are in clinical 
use or advanced pre-clincal studies comprise of monoclonal antibodies and tyrosine 
kinase inhibitors (TKIs) (1).  Several companies have developed monoclonal antibodies 
targeting the extracellular domains of these receptors and preventing activation.  Other 
drugs include the TKIs that enter the cells and target the ATP binding sites, thus 
preventing receptors from phosphorylating target proteins.  See Figure 2 for illustration 
of their mechanisms.  Table 1 below shows current drugs used to target EGFR or ErbB2, 
or both.   
 
 
Figure 2. Current anti-EGFR drugs and the sites at which they target the receptor.   
Reprinted by permission from Elsevier:  Cancer Cell (1), copyright 2006. 
 8 
 
Table 1:  Current ErbB targeting drugs. 
Source: (2) 
Monoclonal 
Antibodies Target 
Tyrosine Kinase 
Inhibitors Target 
Trastuzumab 
(Herceptin) 
ErbB2 Gefitinib (Iressa) EGFR 
Pertuzumab 
(Omnitarg) 
ErbB2 Erlotinib (Tarceva) EGFR 
Cetuximab 
(Erbitux) 
EGFR Lapatinib EGFR /ErbB2 
Matuzumab EGFR EKB-569 EGFR /ErbB2 
Panitumumab EGFR AAE788 EGFR/ErbB2/VEGF 
    CI-1033 EGFR /ErbB2 
 
The drug trastuzumab (Herceptin) by Genetech has been the focus of many 
studies.  Trastuzumab is a monoclonal antibody that binds to the extracellular domain of 
ErbB2.  FDA approved the use of trastuzumab in clinics in 1998.  Several publications 
have shown that in conjunction with adjuvant chemotherapy, trastuzumab lowers the risk 
of recurrence in ErbB2 positive breast cancer patients, compared to chemotherapy alone 
(29-31) and has significant effect on patient survivorship (32).  However, trastuzumab, 
like the rest of the monoclonal antibody drugs, is controversial because of its cost in 
production. 
The introduction of the tyrosine kinase inhibitors as therapeutics has been more 
recent.  These drugs can target either EGFR or both EGFR and ErbB2 receptors.  Among 
these inhibitors, gefitinib and erlotinib both target only one receptor, EGFR, while newer 
FDA approved drugs, such as Lapatinib target both EGFR and ErbB2.  Increased 
expression of EGFR and ErbB2 occurs in about 30% of breast cancers and since these 
two receptors are heterodimer partners, strategies in which the use of drugs like Lapatinib 
or combination of drugs are being considered for clinical trials. 
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Several studies have shown that targeting both EGFR and ErbB2 may have 
synergistic effects on proliferation for the BT474 and SkBr3 breast tumor cell lines (33).  
Our work focuses on Lapatinib because it targets both EGFR and ErbB2 that are 
implicated in cancer.  Among the receptor tyrosine kinase inhibitors, it has been shown to 
be most specific to these two receptors, which is important in our study of acquired 
resistance.   
 
LAPATINIB 
Lapatinib is an orally active small molecule tyrosine kinase inhibitor developed 
by GlaxoSmithKline.  This compound is a potent ATP-competitive inhibitor that targets 
EGFR and ErbB2.  In cell free biochemical kinase assays it has been shown to inhibit 
EGFR and ErbB2 tyrosine kinases by 50% (IC50) at concentrations of 10.8 and 9.3 nM, 
respectively (Rusnak, Lackey et al. 2001).  In a study where the binding affinity of 20 
kinase inhibitors for 100 different kinases were screened, Lapatinib was found to be the 
most specific because it bound EGFR and ErbB2 almost exclusively (34). Compared to 
other ErbB receptor tyrosine kinase inhibitors, Lapatinib has slower dissociation from 
receptor, resulting in prolonged effect on receptor downregulation (35).  In vitro, it has 
been shown that Lapatinib blocks EGFR and ErbB2 phosphorylation and decreases 
phosphorylation of downstream MAPK and Akt (36).  Lapatinib has shown to have anti-
proliferative effects on breast and lung cancer cells (37, 38).  In cell lines across multiple 
tumor types, it has been observed that Lapatinib-treated cancer cells undergo apoptosis or 
G1 cycle arrest (39, 40).    
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In phase I clinical studies, Lapatinib was tolerated up to 1800 mg once daily in 
breast cancer patients, with side effects of diarrhea, nausea, rash, fatigue, anorexia, and 
vomiting.  Clinical activity was observed at a minimum of 650 mg/day (41).  
Pharmacokinetic data from these studies showed serum level of Lapatinib peaked 4 hours 
after dosing, accumulate two fold with daily dosing, with steady state achieved in 7 days.  
A phase II trial showed that Lapatinib was effective in approximately 20% of patients 
with ErbB2-positive metastatic breast cancer who had not received first-line 
chemotherapy (42).  In a phase III trial, it was demonstrated that women with ErbB2-
positive metastatic breast cancer benefit from Lapatinib, whereas ErbB2-negative breast 
cancer did not (43).  In 2007, FDA approved Lapatinib for use in combination with 
capecitabine for patients (previously treated with anthracycline, taxane, or trastuzumab) 
who have metastatic breast cancer that overexpresses ErbB2 (44), after several phase III 
trials that demonstrated the synergistic effect compared to either alone (45-47).   
 Lapatinib offers improvements over trastuzumab.  Aside from its specificity to 
EGFR and ErbB2, Lapatinib induces apoptosis in trastuzumab-resistant breast SkBr3 
cancer cells (48).  In 2009, Scaltriti et. al showed that Lapatinib enhances the effects of 
trastuzumab in MCF7 and SkBr3 breast cancer cell lines (49).  Additionally, Lapatinib’s 
anti-tumor activity was observed in Japanese patients with ErbB2-positive metastatic 
breast cancer that relapsed after trastuzumab-based therapy (50).  Furthermore, several 
studies demonstrated synergistic effects for Lapatinib in combination with trastuzumab in 
xenograft tumor reduction (36, 51). 
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LAPATINIB RESISTANCE 
Therapeutic efficacy of Lapatinib in patient populations is limited by both 
primary and acquired resistance.  Multiple phase II trials have revealed that only 20% to 
35% of patients with ErbB2-positive metastatic breast cancer respond to Lapatinib (42, 
52).   Similar to trastuzumab, the medium duration of response to Lapatinib is less than 
one year (52, 53).  Thus, Lapatinib resistance is a vital issue, especially considering 
ErbB2 is used as a biomarker to initiate Lapatinib treatment in patients.  However, the 
mechanisms of drug sensitivity and acquired resistance are not fully understood at this 
time. 
In an in vitro model, it was discovered that Lapatinib resistance in BT474 breast 
tumor cells was mediated in part by estrogen receptor (ER) and progesterone receptor 
(PR) signaling upregulations in response to Lapatinib, with evidence in increased activity 
in FOXO3a and caveolin-1, as well as Bcl-2 anti-apoptotic protein (38).  Furthermore, 
ErbB2+/ER+ tumor biopsies after 14 days of Lapatinib treatment also reflect increased 
expression of FOXO3a, PR, and Bcl-2.  Consequently combinational treatment with 
tamoxifen demonstrated resistance prevention, suggesting such therapeutic approach is 
appropriate for ErbB2+/ER+ patients (38).   
Within the past decade, many studies have investigated EGFR/ErbB2 tyrosine 
kinase inhibitors and the development of subsequent resistance following treatment in 
lung and breast cancer patients.  The major contributing factor was identified as 
mutations in the kinase domain of EGFR and/or ErbB2.  Recent studies by Tam et. al 
identified mutations in EGFR which confer different degree of sensitivities to gefitinib in 
lung adenocarcinomas (54).  Earlier work by Wang and collaborators discovered that 
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lung cancer NCI-1781 cells with mutated ErbB2 are insensitive to EGFR inhibitors while 
remain sensitive to ErbB2 inhibitors (1).  These studies confirmed that mutations in 
EGFR and ErbB receptors may confer anti-ErbB drug resistance.  However, there have 
been several studies in lung cancer patients harboring specific mutations in EGFR which 
have been linked to increased sensitivity to tyrosine kinase inhibitors, such as gefitinib 
and erlotinib, compared to patients that express wild type EGFR (55-57).  Some groups 
proposed the activation of alternate pathways when EGFR and ErbB2 are inhibited as the 
sources of resistance.  In 2007, Engelman et. al discovered that hepatocyte growth factor 
receptor (MET) amplification leads to gefitinib resistance in lung cancer cells by 
activating ErbB3 leading to increased Akt signaling (58).  Besides the ErbB receptors, 
other molecules have been implicated in ErbB targeted drug resistance.  Activated Src 
and Ras were also implicated as causes of gefitinib resistance by activating either or both 
Akt and MAPK signaling pathways in human gallbladder adenocarcinoma cells (59).  
Another study by Martin et al. reported that in the HCT116 colorectal carcinoma cell line, 
Lapatinib resistance was mediated by elevated induced myeloid leukemia cell 
differentiation protein (MCL-1) and decreased Bcl-2 homologous antagonist/killer 
(BAK) activation, and not by an ErbB mutation (60). 
 
STAT3 
Recent studies have suggested a role for signal transducer and activator of 
transcription 3 (STAT3) in anti-ErbB resistance.  In 2005, Greulich et al. observed that 
cell lines harboring EGFR mutations have increased levels of phosphorylated STAT3 
which correlated with gefitinib sensitivity (61, 62).  Interleukin-6 (IL-6) and STAT3 
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signaling were also linked to cetuximab and radiation resistance in pharyngeal cancer 
(63).  Thus, we hypothesize that STAT3 may play a role in the Lapatinib acquired 
resistance. 
 STAT3 is one of seven members of the STAT family:  STAT1, STAT2, STAT3, 
STAT4, STAT5A, STAT5B, and STAT6.  The proteins of this family have two roles:  1) 
transduce signal through cytoplasm and 2) initiate transcription of genes involved in cell 
cycle, apoptosis, proliferation, survival, differentiation and development (64-66).  STATs 
were originally discovered as mediators of signaling from IL-6 and IFN receptors 
following ligand binding (67, 68).  Each STAT family member responds to specific 
cytokines, and each regulates a specific set of genes.  Following receptor activation, the 
Janus kinase (JAK) family kinases (JAK1, JAK2, JAK3, JYK2) phosphorylates STAT 
proteins.   In response, STATs homodimerize or heterodimerize with other STAT 
members via phosphotyrosine Src homology 2 (SH2) domain interaction.  The dimers 
then translocate to the nucleus where they function as transcription factors for target 
genes, many of which encode for cytokines and growth factors, thus providing a 
mechanism for autocrine and paracine STAT activation (69, 70).   
 Like other STATs, STAT3 is activated by tyrosine phosphorylation in response to 
stimulation by cytokines and growth factors.  Its activation is specifically mediated by IL-
6 cytokine family members, oncostatin M (OSM), and leukemia inhibitory factor, and by 
growth factors such as platelet-derived growth factor (PDGF), fibroblast growth factor 
(FGF), vascular endothelial growth factors (VEGF) and EGF (71-74).  STAT3 is 
phosphorylated at tyrosine residue 705 and at serine residue 727, which results in 
maximal activation of STAT3’s transcriptional activity (75).  In addition to JAK family 
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members, STAT3 is tyrosine phosphorylated by two other types of kinases:  1) receptor 
tyrosine kinases such as EGFR, FGFR, or PDGFR, and 2) nonreceptor-associated 
tyrosine kinases like Src, Ret, or Bcl-Abl protein (76).     
Following tyrosine phosphorylation, STAT3 either homodimerizes or 
heterodimerizes with STAT1, then translocates to the nucleus to begin transcription of 
numerous genes, including survivin, bcl-2, bcl-xL, mcl-1, p21, c-Myc, VEGF, and cyclin 
D1 (74, 77-80).  STAT3 is regulated by several different mechanisms.  Suppressors of 
cytokine signaling (SOCS) proteins attenuate STAT3 activity by inhibiting upstream JAK 
activation (81).  Other mechanisms include protein inhibitors of activated STATs (PIAS) 
proteins and protein tyrosine phosphatases that target STAT3 directly (81-83).   
 Studies have implicated STAT3 in oncogenesis, promoting abnormal apoptosis, 
cell cycle progression, angiogenesis, and tissue invasion (64).  Bromberg et al. in 2002 
demonstrated that STAT3 is required for many cancer cell lines to maintain a 
transformed phenotype (84).  Numerous studies have shown that STAT3 is constitutively 
activated in a variety of cancer types including:  breast (85), prostate (86), leukemia (87), 
lung (88), thyroid (89), and head and neck squamous cell carcinoma (90).  Consequent 
studies show that small molecule tyrosine inhibitors targeting STAT3 activation result in 
growth suppression and apoptosis (87, 91, 92).  Similar effects were observed using 
dominant-negative STAT3 and antisense oligonucleotides (92-94). 
HYPOTHESIS 
 We wanted to show that for a particular breast cancer cell line that acquired 
resistance to Lapatinib is mediated by alterations in the gene regulatory and signaling 
networks.  Specifically in this project, we aimed to characterize the resistant cell line and 
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identify changes in the ErbB signaling proteins and gene expressions that may be 
involved in Lapatinib resistance.  This study consisted of three specific aims.  Aim 1 was 
to develop and characterize a Lapatinib resistant cell line derived from SkBr3, a 
Lapatinib-sensitive breast cancer cell line.  Aim 2 was to identify ErbB signaling network 
changes in the developed resistant cell line and to compare it to the parental line.  Aim 3 
was to determine gene expression changes in the resistant cell line in response to 
Lapatinib.  The details of the study for Aim 1, 2, and 3 will be discussed in chapters 2, 3, 
and 4, respectively. 
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CHAPTER 2:  DEVELOPMENT AND CHARACTERIZATION 
OF RESISTANT CELLS 
 
INTRODUCTION 
 To understand how breast cancers may acquire resistance to Lapatinib, we 
developed a Lapatinib-resistant cell line.  Studies performed by Xia et. al described the 
establishment of a Lapatinib-resistant clonal cell lines using the breast cancer BT474 cell 
line (38).  We adapted their protocol to develop a Lapatinib-resistant SkBr3 breast cancer 
cell line, named SkBr3-R.  The parental SkBr3 cell line, like BT474, has a GI50 value of 
0.03 µM  and is among the most sensitive cell lines to Lapatinib, as shown in Figure 3 
(51, 95).  It is interesting, though not surprising that the most sensitive cell lines all 
overexpress ErbB2. 
In this chapter, the protocol used in establishing the SkBr3-R cell line will be 
discussed first.  The remaining sections of the chapter will report our findings in the 
characterization of this Lapatinib resistant cell line, including cell viability assays that 
verify the increased in Lapatinib resistance. 
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Figure 3. Panel of 47 breast cancer cell lines and their characteristics.  
 A) The cells are ranked based on their sensitivity to Lapatinib, with tissue subtype 
indicated.  B) Overexpression and mutations for certain proteins have been identified for 
the cell lines.  Source:  Communication Drs. Joe Grey and Gordon Mills. 
 
ESTABLISHMENT OF RESISTANT CELLS 
Initially, the SkBr3 cells were grown in Lapatinib at concentration 0.01 µM, well 
below GI50 value of 0.03 µM.  We adopted a set of rules that allowed us to increase 
Lapatinib concentration while maintain viable cells.  First, following each passage (when 
confluency hit 90%), cells were allowed to attach overnight, after which Lapatinib was 
added.  Second, Lapatinib was removed from the media for the remaining time of that 
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passage whenever confluency stalled for more than two weeks.  Third, the media were 
refreshed every three to six days, depending on the confluency.  Our prior protocol called 
for Lapatinib-containing media to be refreshed every day; however, that resulted in non-
viable plates after two to three weeks.  This modification of changing from continuous 
exposure to periodic acute exposure of Lapatinib allowed the concentration-increasing 
process to continue past the one month time point.  Fourth, we increased Lapatinib 
concentration only after a minimum of four successful passages.  Fifth, regarding the 
pace of concentration increase, we doubled the concentration until 0.2 µM was reached, 
at which point we increased at increments of 0.2 µM.    After 12 months, the Lapatinib-
insensitive SkBr3-R reached 1.5 µM and could not tolerate higher concentrations.  We 
attempted single-cell cloning but were unsuccessful.  Two techniques were tested:  
cloning cylinder isolation of cells and 96-well serial dilution cell isolation.  Both resulted 
in non-viable wells of cells after three weeks.  Subsequently, using the pooled SkBr3-R 
cells we performed Lapatinib dose response assays to determine the cells’ GI50 value. 
Cell viability assays confirmed a right shift in the dose response curve for the 
resistant cell line, which we named SkBr3-R, with GI50 value at 2.6 µM, over 100 fold 
decrease in sensitivity compared to the parental cell line.  See Figure 4.   
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MATERIALS AND METHODS 
Cell lines and reagents  
 
 SkBr3 breast cancer cell line was obtained from UT M.D. Anderson Cancer 
Center Characterized Cell Line Core Services.  Both SkBr3 and SkBr3-R cell lines were 
characterized by Core Services to be related and known mutations verified.  Cells were 
routinely maintained in RPMI 1640 (Invitrogen, Carlsbad, California) supplemented with 
10% fetal bovine serum (FBS)( Sigma-Aldrich, St. Louis, Missouri) and 
penicillin/streptomycin (Mediatech, Manassas, Virginia).  Other cell culture supplies 
include trypsin-EDTA (Invitrogen, Carlsbad, California), cloning discs (Fisher Scientific, 
Waltham, Massachusetts), phosphate buffered saline (PBS) (Mediatech, Manassas, 
Virginia).  Lapatinib (LC Laboratories, Woburn, Massachusetts) was dissolved in 
dimethyl sulfoxide (DMSO) from EMD.  Triton X-100 (EMD, Gibbstown, New Jersey), 
RNase A(Fisher Scientific, Waltham, Massachusetts), propidium iodide (MP 
Biomedicals, Solon, Ohio), and ethanol (Pharmaco-Aaper, Brookfield, Connecticut) were 
used to fix and stain cells in cell cycle analyses.   Crystal violet (Sigma-Aldrich, St. 
Louis, Missouri), sodium citrate (Fisher Scientific, Waltham, Massachusetts), methanol 
(Ricca Chemical Co, Arlington, Texas) were used in crystal violet cell viability assays.  
Bovine serum albumin (BSA)(Fisher Scientific, Waltham, Massachusetts) was used for 
western blots.  For DNA gel electrophoresis, we used ethidium bromide (EMD, 
Gibbstown, New Jersey) and agarose (EMD, Gibbstown, New Jersey).  
Antibodies 
 
The following antibodies were used for immunoblotting: anti-phospho-EGFR 
(Y1068); anti-phospho-EGFR(Y992); anti-phospho-EGFR (Y1045); anti-phospho-EGFR 
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(Y845); anti-phospho-HER3/ErbB3 (Y1289); anti-phospho-HER2/ErbB2 (Y1248); anti-
EGFR; anti-ErbB2; anti-ErbB3; anti-ErbB4;  (Cell Signaling Technology, Boston, 
Massachusetts); and anti-β-Actin (Sigma-Aldrich, St. Louis, Missouri).   
Cell viability assay 
 
 Cells were seeded (5 x103 per well) in 96-well plates.  Next day, cells were 
treated with Lapatinib for 8 concentrations (0, 0.01, 0.05, 0.10, 0.5, 1.0, 5.0, 10.0, 25.0 
µM) and for another 8 concentrations (0, 0.1, 0.5, 1.0, 5.0, 10.0, 50.0, 100.0 µM).  At the 
0, 48, 96, 120 hour time points, plates were collected for reading.  Volume of 50µL of 
crystal violet solution (0.5% crystal violet w/v, 20% methanol v/v) was added to each 
well to allow staining for 10 minutes, followed by gentle rinse with water to remove 
excess stain.  Once dried, the wells were filled with 100µL of sorensins buffer (0.1M 
sodium citrate [pH4.2], 50% v/v ethanol) to redissolve crystal.  After one hour with the 
crystal violet uniformly dissolved, cell viability was determined by measuring the 
absorbance at 570nm using a Vmax kinetic microplate reader (Molecular Devices, 
Sunnyvale, California).  Each sample was measured in quintuplicate. 
SDS-PAGE and immunoblotting 
 
 Assays were performed as previously described (96).  SkBr3 and SkBr3-R cells 
were seeded in 6-well plates (500,000 cells per well) in triplicates.  The following day, 
cells were treated with Lapatinib at 1 µM.  Controls were DMSO used in equal volumes.   
Cells were lysed by incubation on ice for 15 minutes in a sample lysis buffer (50 mM 
Hepes, 150 mM NaCl, 1 mM EGTA, 10 mM sodium prophosphate, pH 7.4, 100 nM NaF, 
1.5 mM MgCl2, 10% glycerol, 1% Triton X-100 plus protease inhibitors; aprotinin, 
bestatin, leupeptin, E-64, and pepstatin A).  Cell lysates were centrifuged at 15,000 g for 
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20 minutes at 4°C. The supernatant was frozen and stored at −20°C.  Protein 
concentrations were determined using a protein-assay system (BCA, Bio-Rad, Hercules, 
California), with BSA as a standard. For immunoblotting, proteins (25 µg) were 
separated by SDS-PAGE and transferred to Hybond-C membrane (GE Healthcare, 
Piscataway, New Jersey).  Blots were blocked with 3% BSA TBS-T for 60 minutes and 
incubated with primary antibodies overnight, followed by goat anti-mouse IgG-HRP 
(1[ratio]30,000; Cell Signaling Technology, Boston, Massachusetts) or goat anti-rabbit 
IgG-HRP (1[ratio]10,000; Cell Signaling Technology) for 1 hour.  Secondary antibodies 
were detected by enhanced chemiluminescence (ECL) reagent (GE Healthcare, 
Piscataway, New Jersey).  Quantification of bands were performed by ImageJ (National 
Institutes of Health). 
Polymerase chain reaction 
 
 DNA templates were isolated from cells using FlexiGene DNA Isolation kit 
(QIAGEN).  Primers were designed using Primer3 Online (See Appendix A for primer 
sequences).   PCR master mix consisted of the following µL amount per sample:  10x Hif 
buffer 2.5, dNTPs 1.5, forward primer (0.05µg/µL) 1, reverse primer (0.05µg/µL) 1, Taq 
Hif 0.2, MgSO4 0.5, H2O 8.3, DNA template (1µg) 10.  Total volume per PCR reaction 
was 25µL.  PCR reactions were carried out in Bio-Rad MyCycler thermal cycler 
(SN#580BR).  Two sets of PCR programs were used:  1) [94C, 2’ (94C, 30”; 54C, 30”; 
68”, 1’) 35 cycles, 68C, 10’; hold 4C] and 2) [94C, 2’ (94C, 30”; 60C, 30”; 68”, 1’) 35 cycles, 
68C, 10’; hold 4C].  
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 Sequencing 
 
 PCR products were visualized using ethidium bromide on a 1% agarose gel and 
separated based on product size using electrophoresis.  Desired DNA fragments were 
extracted from PCR products using QIAquick PCR Purification Kit (QIAGEN).  DNA 
samples were submitted to UT M.D. Anderson Cancer Center DNA Core Services for 
sequencing. 
Wound healing assay 
 
 SkBr3 and SkBr3R cell lines were plated to confluency in 6-well plates and 
treated with Lapatinib (1 µM) or DMSO for 24 hours prior to scratches with a sterile 
P200 pipette tip (SureOne:  Fisher Scientific, Pittsburg, PA).  The scratch was 
photographed with an inverted microscope (Eclipse TE2000E: Nikon, Melville, NY) over 
a 3 days period after medium was refreshed to observe any healing migration. 
Matrigel invasion assay 
 
 BD BioCoat matrigel Invasion Chamber (BD Biosciences) was utilized.  
Following rehydration of Matrigel inserts and control inserts, cells were seeded (5x104 
cells/mL) in a 24-well chamber plate in triplicates per condition.  FBS was used as 
chemoattractant, Lapatinib was used at 1 µM.  Inserts were transferred to wells 
containing FBS and cells were placed on inserts.  The chamber plate was incubated for 22 
hours in a humidified tissue culture incubator, at 37C, 5% CO2 atmosphere.  After 
staining, cells were counted per Matrigel.  Analysis was performed by calculating % 
invasion using ratio of cells invading through Matrigel insert to cells migrating through 
control insert.  Invasion Index = % Invasion Test Cell / % Invasion Control Cell. 
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Cell cycle analysis 
 
 Cells were seeded into 6-well plates in triplicates, with consideration of the 50-
hour doubling rate, growth retardation by Lapatinib, and harvesting at confluency of 70-
90%.  Harvesting time points were day 0 (when 1 µM Lapatinib was added), day 2, day 
4, and day 6.  At each harvest, cells were trypsinized for 2-5 minutes, resuspended in 
medium, followed by centrifugation for 6 minutes at 200g at room temperature.  After 
two centrifugations to remove supernatant using media containing serum, cells were 
counted and single-cell-resuspended in PBS (1x106 to 107 cells in 0.5mL).  Cells mixture 
was added to 4.5mL of 70% ethanol in 12x75mm centrifuge tubes for fixation and kept in 
4C for storage (2 hours minimum).  After all time points collected, the samples were 
resuspended in 5mL PBS, centrifuged after which supernatant was decanted.  The cells 
were incubated at room temperature for 30 minutes with 1mL propidium iodide staining 
solution (0.1%(v/v) Triton X-100 in PBS, 0.2mg/mL RNase A, 0.02mg/mL propidium 
iodide).  Cell fluorescence was measured by flow cytometry.  For each sample, 20000 
cells were scanned.  Analyses of data were done with DNA content histogram 
deconvolution software Cell Quest Pro. 
Annexin V apoptosis assay 
 
 Cells were seeded into 6-well plates (500,000 per well) in triplicates.  Following 
day, cells were treated with Lapatinib (1 µM).  Controls were DMSO used in equal 
volume.   At the 24 and 48 hour time points, cells were washed by cold PBS, trypsinized, 
and resuspended in 1X binding buffer (10X Binding Buffer:  0.1 M Hepes, pH 7.4; 1.4 M 
NaCl; 25 mM CaCl2) at a concentration of 1 x 106 cells/mL.  100µL of cell mixture was 
added to 5mL culture tube where it was stained with 2µL Annexin V-FITC solution (BD 
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Biosciences).  After gentle mix and incubation for 15 min at room temperature in the 
dark, 400µL of 1X binding buffer was added to each tube.  Addition of propidium iodide 
staining solution was followed immediately by analysis by flow cytometry, performed at 
the UT M.D. Anderson FACS Services department.  Controls included unstained cells, 
Annexin V-FITC stained and propidium iodide (to account for sub G1 cells) stained 
samples. 
Statistical analysis 
 
 Microsoft Excel and GraphPad prism software (GraphPad Software) were utilized 
in the analyses of cell viability assays and generation of bar graphs and boxplots.   
 
RESULTS 
No differences in ErbB receptor levels or phosphorylations between sensitive and 
resistant cells 
 
 To assess whether change in sensitivity to Lapatinib is characterized by changes 
at the receptor level, we performed immunoblotting using antibodies against total EGFR 
and ErbB2 and found no significant differences between the two cell lines in their ErbB 
receptor protein expressions, with or without Lapatinib treatment (48 hours).  See Figure 
5.  Concentration of Lapatinib used was 1 µM because it was the concentration at which 
resistance cells were maintained; above GI50 value of sensitive but below that of resistant 
cells.  It has been previously shown that Lapatinib-resistant BT474 cells do not differ 
from its parental Lapatinib-sensitive cells in ErbB receptor expression (38).  Thus, we 
find our result similar to that of Xia’s group.  We also examined the effect of Lapatinib 
on the phosphorylation of the ErbB receptors, after 48 hours of treatment.  Again, similar 
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to Xia’s reported results, Lapatinib decreased phosphorylated EGFR and ErbB2 in both 
the sensitive and resistant cells. 
 It was previously demonstrated in BT474 and SkBr3 cells that gefitinib (another 
anti-ErbB TKI drug) decreases both EGFR and ErbB2 phosphorylations.  In another 
study, gefitinib was shown to initially inhibit the phosphorylation of ErbB3 but loses its 
suppression after 48 hours (97).  In our cell lines we did not observe differential changes 
in EGFR or ErbB2 phosphorylation upon exposure to Lapatinib, that is, Lapatinib 
similarly inhibits receptor activity for both cell lines.  Based on the data, we hypothesized 
that ErbB receptors do not contribute to Lapatinib resistance. 
Since mutations in the ErbB receptors have been found in previous cases of other 
tyrosine kinase inhibitors’ resistances, we sequenced exons (exons 18, 19, 20, 21, 22, and 
25 in EGFR, exons 19, 20, 21, 22 in ErbB2, and exons 20 in ErbB3) in the ErbB 
receptors where mutations have been reported in breast and lung cancer (98-100).  In our 
analyses, both cell lines did not have any mutations within these exons.  Unless mutations 
occurred in the complement set of exons for these receptors, the mechanisms of 
resistance may lie downstream. 
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Resistant cells have higher invasive index 
 
Previous studies have found that in the acquisition of resistance to a drug, cell 
lines often significantly increase their invasive and mobile nature—like MCF7 breast 
carcinoma cells resistant to tamoxifen (101),  HCT116 colorectal carcinoma cells 
resistant to Lapatinib (60), and A549 lung carcinoma cells resistant to gefitinib (102).  
We performed wound healing and Matrigel invasion assays to determine if the resistant 
cells have increased invasiveness and mobility.  From the results of the Matrigel invasion 
assay, we determined the resistant cells have a higher invasive index value than the 
sensitive (1.42±0.07 vs. 1.00±0.10).  However, in the presence of Lapatinib, their 
invasive indices are not significantly different.  See Figure 6. 
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Figure 6.  Matrigel invasion assay shows resistant cells have higher invasive index 
than the sensitive cells. 
Matrigel assay shows that the resistant cells have a higher basal invasion index (1.4) 
as compared to the parental cells (1.0), significant with p<0.05.  Lapatinib treatment 
reduced the invasion index of both parental and resistant cells. 
  
 
The effect of Lapatinib on sensitive and resistant cells’ mobility was observed 
using wound healing assay.  See Figure 7.  Both cell lines had similar profiles within the 
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first 24 hours (103), with no detectable wound healing.  In the absence of Lapatinib, both 
sensitive and resistant cells slowly grew in the wound area over the period of three days.  
In the presence of Lapatinib, both cell lines reflected even slower wound healing over the 
three days period.  Considering wound healing typically occurs within the first 24 hours, 
we conclude the resistant cells’ migrative capacity is similar to the sensitive cells, which 
is minimal.  
 
Figure 7.  Wound healing scratch assay to measure cell migration.   
Results from the scratch assay shows no difference between sensitive SkBr3 and 
Lapatinib resistant SkBr3-R cells, at Days 1-3.  In the presence of Lapatinib, there was 
no difference on day 1 and the differences observed on day 2 and 3 are a function of 
decreased cell numbers in the Lapatinib treated sensitive cells.  
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Cell cycle distributions  between resistant and sensitive 
 
It was previously demonstrated that Lapatinib-treated cancer cells undergo 
apoptosis or G1 cycle arrest (39, 40).   From our dose response cell viability assays, we 
discovered sensitive cells start to die after two days of 1 µM Lapatinib treatment, with 
greater contrast between sensitive and resistant cells after six days.  In order to stratify 
that contrast, we performed the cell cycle analysis to identify sub G0/G1, G1, S, and G2M 
subpopulations.  Aside from cell cycle phase distributional changes, we wanted to know 
if the resistance cells evade cell cycle arrest; and if not, whether they evade apoptosis 
within this time frame (of three normal doubling cycles).  Figure 8 shows the results from 
four time points collected after Lapatinib addition:  days 0, 2, 4, and 6. 
At day 0, prior to the addition of Lapatinib, both cell lines had similar cell cycle 
distribution:  49% cells in G1 phase, 15% in S phase, 33% in G2 and M phases, and 3% 
spontaneous deaths on average.  Two days after the Lapatinib treatment, G1 phase cell 
number increased in both cell lines, up to 70%, where as in the control groups, G1 
subpopulation remains closer to 50%.  Though there were more cells in S phase in the 
resistant cell line, the sensitive cell line had significantly more dead cells, increased from 
3% to 7%.  Deaths in resistant cell lines remain at 3%, with or without Lapatinib 
conditions.  On day 4, deaths jumped to 21% in sensitive cells treated to Lapatinib, 
compared to 5% in control.  Resistant cells’ deaths remain low for both control and 
Lapatinib condition, 5% and 7% respectively .  Also to note at day 4 is that there was a 
higher percent of resistant cells in G1 arrest than of sensitive cells, though that difference 
can be mirrored in the sensitive cells’ dead population increase.  
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Figure 8.  Cell cycle analysis. 
Using FACS of 20,000 cells per condition, per day, collected at days 0, 2, 4, and 6 with 
and without Lapatinib treatment.  A).  Sensitive and resistant cells were treated with 
vehicle (columns 1 and 3) or 1 µM Lapatinib (columns 2 and 4) and cell cycle assayed 
by FACS analysis.  B-D) Cell cycle analysis of sensitive and resistant cells on days 2, 
4,6 without Lapatinib (columns 1 and 3) and with Lapatinib (columns 2 and 4).   
Lapatinib treatment had similar effect on the cell cycle for both sensitive and resistance 
cells leading to increase in cells with G1 arrest.  In the sensitive cells there was a 
significant increase in cell death and by day 6 up to 66% of the cells were dead, while in 
the resistant cells only 18% were dead cells. 
Finally, after six days of Lapatinib treatment, deaths in sensitive cells skyrocketed 
to 66%, compared to accumulation of cell deaths at 8% in control condition.  In the 
resistant cells, deaths increased to 18%, with control condition deaths at 7%. 
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Figure 9.  Cell cycle analysis of only live cells. 
Days 0, 2, 4, and 6 after Lapatinib (1 µM) treatment.  Deceased cells were excluded 
from the analysis as seen in Figure 9.  Lapatinib treated cells entered G1 arrest, evident 
at day2 and day4.  Day6 indicated smaller percentages of G1 arrested cells in both cell 
lines, compared to days 2 and 4. 
At this point, cell deaths appear to be the main defining difference between the 
sensitive and resistant cells.  A significant subpopulation of resistant cells do evade 
apoptosis, thus answering our first question.  To answer whether resistant cells evade G1 
arrest, we re-examined the data by excluding the dead cells of our results and rescaled the 
population percentages of G1, S, and G2M such that the sum is 100%.  See Figure 9.  Two 
days after Lapatinib treatment, both sensitive and resistant cells increased G1 
subpopulation to 70%.  At day 4, G1 subpopulation increased further to 75% in both cell 
lines.  At day 6, G1 subpopulation drops below 70% for both cell lines.  Thus, for cells 
that evade Lapatinib-induced apoptosis, it appears they eventually escape G1 arrest as 
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well.  However, this hypothesis assumes no new cells proliferated, which was the case 
here since confluency increased over the days in the wells containing the resistant cells.  
Whether resistant cells escape G1 arrest in addition to apoptosis remain uncertain at this 
point and may require studying extended time frame of more than three doubling 
generations. 
 
Early apoptosis occurs in sensitive cells at 48hours 
 
 Since the major defining difference between the sensitive and resistant cells is cell 
deaths, we performed an apoptosis assay, Annexin V, to identify and separate cells in 
early apoptosis (when phosphatidylserine flips to extracellular membrane layer, marking 
the cell for phagocytosis), in late apoptosis/necrosis, and in necrosis after 48 hour 
treatment with Lapatinib at 1µM.  See Figure 10.  As before, the population of 
spontaneous dead cells was below 5% at the 48 hour time point (Figure 10A).  For cells 
in late apoptosis and cells in necrosis, the populations were comparable across the 
conditions with exception of the resistant cells treated with Lapatinib, which was lower 
(Figure 10B).  Finally, the subpopulations of cells undergoing early apoptosis provided 
greater contrast between the sensitive and resistant cell lines, showing almost three fold 
increase in cells in early apoptosis after 48 hour Lapatinib treatment, in the sensitive cells 
compared to the resistant cells (Figure 10C). 
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Figure 10.  Identification of three subpopulations of dead and dying cells after 1 µM 
Lapatinib treatment for 48hours. 
Fewer resistant cells underwent apoptosis.  A) Necrotic cell populations were below 5% for 
all conditions.  B) Lower population of late apoptotic and necrotic cells in the SkBr3-R cells 
treated with Lapatinib.  C) Lower population of early apoptotic cell populations with/without 
Lapatinib for the resistant cells.  Thus, sensitive cells have significantly higher population of 
cells in early apoptosis after Lapatinib exposure. 
 
CONCLUSIONS 
 
 Mechanisms have been proposed for the development of acquired resistance to 
anti-ErbB therapies.  One such proposal is that resistance is caused by mutations 
developed in the ErbB receptors.  Numerous studies with other ErbB targeted drugs in 
various cancer types have discovered mutations in the EGFR (54-57) and ErbB2 (1, 104), 
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receptors that render cells to be insensitive to the drugs.  Specific to Lapatinib, it was 
found in HCT116 cells that resistance is mediated by elevated MCL-1 and decreased 
BAK and not by ErbB mutation (60).  However, in a recent study, randomly mutagenized 
ErbB2 expression library screen in murine bone marrow–derived Ba/F3 cells identified 
16 mutations in ErbB2 (spanning from exons 11 to 27, many in the kinase domain) that 
affect sensitivity to Lapatinib (105).  The exons that we sequenced for EGFR, ErbB2, and 
ErbB3 did not have mutations.  At the time, our defined set of mutational hotspots only 
included exons 19-22 for ErbB2.  Thus, since we did not sequence all exons of these 
receptors, we do not know fully if mutations did developed in these receptors in the 
resistant cell line during resistance acquisition.  We do know that mutations did not 
develop for EGFR exons 18-22, 25, ErbB2 exons 19-22, and ErbB3 exon 20.  However, 
together with our results where we examined phosphorylated and total ErbB receptors 
and discovered similar basal and response to Lapatinib in both sensitive and resistant 
cells, it is likely that no kinase domain mutations occurred in the exons for which we did 
not sequence.  Nevertheless, further sequencing for all the ErbB receptor exons is needed 
to fully answer the question of whether mutations occurred in the ErbB receptors during 
acquisition of Lapatinib resistance. 
 We sought to determine if Lapatinib resistance was attributed by increase in 
migrative and invasive capacity.  A previous study demonstrated adaptation in growth in 
A431-GR squamous cancer cells that had developed resistance to gefitinib from A431 
cells; in 3D Matrigel, the resistant cells were able to form large colonies whereas the 
parental cells had impaired growth (106).  Another gefitinib-resistant prostate cancer cell 
line PC3-GR was found by Boyden chamber assays to exhibit 2-fold greater migration 
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capability (107).  Our wound healing assays indicated the resistant SkBr3-R cells have 
similar wound healing capacity compared to the sensitive cells.  However, Matrigel assay 
demonstrated the resistant cells have higher invasive index than the sensitive cells.  In 
this respect, Lapatinib resistance may contribute to an aggressive phenotype, similar to 
the case with gefitinib (106).   
 We made the observation during our proliferative assays that Lapatinib treatment 
at 1 µM was sufficient to demonstrate contrast between the sensitive and resistant cells.  
The cell cycle analysis performed using that concentration stratified the contrast and 
indicated difference in sub-G0/G1 populations.  Lapatinib effectively induced G0/G1 arrest 
in both cell lines initially, but as the days passed more of the sensitive cells in cell cycle 
arrest underwent apoptosis.  Since the cell cycle analysis does not identify live cells 
undergoing apoptosis, we performed Annexin V assay which differentiate live cells 
undergoing apoptosis from cells in late apoptosis and necrotic cells.  From the apoptosis 
assay, we found significant difference in early apoptosis subpopulations between in the 
sensitive cells and resistant cells 48 hours after Lapatinib treatment.  In the resistant cell 
line, the arrested cell population eventually decreased while sub-G0/G1 cells increased 
slowly (spontaneous deaths accumulated).  When discarding the population of difference 
(sub-G0/G1) and considering only the live population, the cell cycle distributions of both 
cell lines appeared similar.  This observation can be explained by either the result of 
either a mechanism that allows the resistant cells to continue cell cycle progression into 
the S phase or of the outgrowth of a subpopulation that does not undergo cell cycle arrest 
in response to Lapatinib.  The latter case is possible since our SkBr3-R cell line is a 
pooled cell line. 
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CHAPTER 3 STAT3 SIGNALING ACTIVITY IN RESISTANT CELLS 
 
INTRODUCTION 
 STAT3 is a signal transducer and transcription factor and has been found to be 
constitutively active in various tumor types (84-90).  As research continues in elucidating 
the role of STAT3 in tumorigenesis, increasing evidence implicates STAT3’s role in 
growth and survival dysregulation, angiogenesis promotion, immune suppression, and 
invasion and metastasis (64, 90, 108).  Furthermore, recent studies have implicated 
STAT3 in cancer resistant to anti-ErbB drugs, such as gefitinib and cetuximab (61-63).   
 We discovered a correlation between STAT3 phosphorylation and Lapatinib 
sensitivity in a panel of breast cancer cell lines that were assayed using reverse phase 
protein array (RPPA).  See Figure 11.  Going from left to right are the cell lines in their 
order of increasing Lapatinib resistance.  With the exception of SkBr3 cell line, the levels 
of phosphorylated STAT3 at tyrosine 705 increased with increased Lapatinib-resistance. 
 In our characterizations of the SkBr3 and SkBr3-R cell lines, we found the 
resistant SkBr3-R cells have higher invasive index than the sensitive cells.  We also 
found that the resistant cells evade apoptosis after Lapatinib exposure whereas many of 
the sensitive cells did not.  Considering STAT3’s role in invasion, metastasis, survival, 
and its recent link in resistance to other ErbB inhibitors, we investigated STAT3’s role in 
acquired Lapatinib resistance. 
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Figure 11.  RPPA analysis of phospho STAT3 Y705 levels on a panel of breast cell 
lines. 
Increasing levels of phospho Y705 STAT3 shows correlation with increasing 
Lapatinib resistance among breast tumor cell lines, with the exception of SkBr3 
which show basal level of STAT3 phosphorylation. 
 
MATERIALS AND METHODS 
Cell lines and reagents 
 
SkBr3 breast cancer cell line was obtained from UT M.D. Anderson Cancer 
Center Characterized Cell Line Core Services.  Cells were routinely maintained in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin.  
Lapatinib was purchased from LC Laboratories and dissolved in dimethyl sulfoxide 
(DMSO).  Ly6E luciferase construct (1ug/mL) and beta-galactosidase construct (1ug/mL) 
were previously obtained from Dr. J Darnell Jr. (Rockefeller University, NY).  Luciferase 
assay system kit (E1501) and reporter lysis buffer 5X (E397A) (Promega, Madison, 
Wisconsin) and beta-galactosidase assay reagents (Clonetech cat#631712, Mountain 
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View, California) were used for luciferase reporter assay.  JetPRIME transfection kit was 
purchased from Polyplus Transfection, Inc (New York, New York) for the DNA 
transfection experiments. Reagents used in immunofluorescence assays include 
phalloidin (Oregon Green 488)( Invitrogen, Carlsbad, California), paraformaldehyde 
(USB Corp, Cleveland, Ohio), and DAPI (Sigma-Aldrich, St. Louis, Missouri).  
STATTIC (EMD, Gibbstown, New Jersey) stock solution was made at 50mM using 
DMSO. 
Antibodies 
 
 The following antibodies were used for immunoblotting: anti-phospho-
STAT3(Y705); anti-phospho-STAT3(S727); anti-STAT3;  Anti-rabbit IgG (H+L), 
F(ab')2 Fragment (Alexa Fluor® 647 Conjugate) (#4414 )(Cell Signaling Technology, 
Boston, Massachusetts); and anti-β-Actin (Sigma-Aldrich, St. Louis, Missouri).  
Reverse phase protein array 
 
 Assays were performed as previously described (109).  Cells were seeded 
(300,000 per well) in 6-well plates in triplicates.  Next day, cells were treated with 
Lapatinib at 1 µM for 4 hours, followed lysis using lysis buffer (as prepared for 
immunoblotting).  Controls were DMSO used in equal volumes.  In 1% SDS, cell lysates 
(1 µg/µl) were boiled and hybridized under stringent conditions.  Using a GeneTac G3 
DNA arrayer (Genomic Solutions, Ann Arbor, MI, USA), seven two-fold serial dilutions 
of cell lysates are arrayed on multiple nitrocellulose-coated glass slides (FAST Slides, 
Whatman Schleicher & Schuell, Keene, NH, USA).  RPPA slides were produced in 
batches of 20.  Printed slides were stored in desiccant at –20°C.  Antibodies were 
screened for specificity by Western blotting with 25 µg of lysate protein per lane.  An 
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antibody was accepted only if it produced a single predominant band at the expected 
molecular weight and if it behaved similarly between immunoblotting and RPPA across a 
dynamic range.  Each slide was incubated with specific primary antibody, which was 
detected by using the catalyzed signal amplification (CSA) system (DAKO, Carpinteria, 
CA, USA).  Briefly, each slide was washed in a mild stripping solution of Re-Blot Plus 
(Chemicon International, Temecula, CA, USA) then blocked with I-block (Tropix, 
Bedford, MA, USA) for 30 minutes. Following the DAKO universal staining system, 
slides were then incubated with hydrogen peroxide, followed by avidin for 5 minutes, and 
biotin for 5 minutes.  Slides were incubated with primary and secondary antibodies then 
incubated with streptavidin-peroxidase for 15 minutes, biotinyl tyramide (for 
amplification) for 15 minutes, and 3,3-diaminobenzidine tetrahydrochloride chromogen 
for 5 minutes.   Between steps, the slide was washed with TBS-T buffer.  Loading is 
determined by comparing phosphorylated and nonphosphorylated antibodies. Multiple 
controls are placed on each slide to facilitate quantification and validation of the assay.  
Spot intensity was measured using MicroVigene by VigeneTech.  Protein 
phosphorylation levels are expressed as a ratio to equivalent total proteins.  Fold 
increases in spot intensities were calculated against nonstimulated control samples. 
Transfection with reporter constructs 
 
 SkBr3 and SkBr3-R cells were seeded in 6-well plates (500,000 cells per well) in 
triplicates.  The following day, the cells were co-transfected with Ly6E-luciferase and 
beta-galactosidase constructs [4:1 Ly6E:b-gal ratio (w/w)] using Polyplus transfection 
jetPRIME reagent at 1:2 DNA:jetPRIME ratio (w/v).  One µg of DNA was diluted into 
200µL jetPRIME buffer, followed by vortexing.  Two µL jetPRIME was added.  The 
 42 
 
mixture was vortex for 10 seconds and spun down briefly.  After incubation at room 
temperature for 10 minutes, 100µL of mixture was added dropwise to the cells, which 
were in 1mL medium.  Transfection was allowed to occur 24 hours before replacement of 
transfection medium by complete medium.  48 hours after initial transfection, the cells 
were exposed to 1 µM Lapatinib.  Controls were DMSO used in equal volumes.   
Luciferase assay 
 
 Twenty-four hours after Lapatinib treatment, the cells were collected, washed 
with PBS and lysed with 100µL reporter lysis buffer.  Lysates were freeze-thawed to lyse 
the cells completely, scraped and transferred to microcentrifuge tubes and kept on ice.  
Following 10 second vortex, the tubes were centrifuged at 12000g for 15 seconds.  The 
supernatant was then used for the luciferase signal readout.  With all reagents and 
samples at room temperature, 100µL of luciferase assay reagent was aliquot into each 
illuminometer tube.  20µL of sample lysate was added to each tube, followed by 
immediate reading on the Monolight 3010 illuminometer.  The illuminometer was set to 
perform 2-sec measurement delay followed by 10-sec measurement read.  The control 
used was 20µL of lysis buffer alone.  To account for the number of cells successfully 
transfected, beta-galactosidase reporter system was used.  For each sample, 100µL of 
beta-galactosidase assay reagent was added to an illuminometer tube prior to the addition 
of the sample, which was in the amount of 10µL.  Sample lysates were added to the 
tubes.  Samples were incubated for an hour at room temperature and the tubes were 
placed in the illuminometer for reading.  The control was 10µL of lysis buffer alone.  
Luciferase readout of each sample required background subtraction from control readout, 
followed by division by the corresponding beta-galactosidase readout for that sample.   
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Immunofluorescence imaging 
 
 SkBr3 and SkBr3-R cells were seeded (10000, 5000, 2500 per well per row) in 
Packard Bell 96-well immunofluorescence plates.  Each condition was done in triplicates.  
The following day, cells were treated with Lapatinib at 1 µM.  Controls were DMSO 
used in equal volumes.  After 48 hours, the cells were washed with PBS two times.  The 
wells were then covered to a depth of 2-3mm with 4% formaldehyde in PBS.  Cells were 
allowed to fix for 15 minutes at room temperature.  Fixative was then aspirated and the 
wells were rinsed three times in PBS for five minutes each.  The cells were then 
permeabilized with 0.3% TritonX-100/PBS for 10 minutes and rinsed again with PBS for 
5 minutes.  After rinse, the cells were blocked in 0.3% TritonX-100/PBS with 5% BSA 
for 60 minutes.  The blocking solution was aspirated and cells were incubated with anti-
phospho-STAT3 (Y705) diluted (1 to 100 ratio) in 200µL of 0.3% TritonX-100/PBS.  
Primary antibody incubation lasted 48 hours at 4C.  After three rinses in PBS for five 
minutes each, the cells were incubated in fluorochrome-conjugated secondary antibody 
diluted (10ug/mL) in 200µL PBS/Triton for two hours at room temperature in the dark.  
At this point, cells were stained sequentially with fluorescent nuclear stain DAPI and 
actin stain phalloidin.  Each stain was diluted 1:100 in 200µL PBS and incubation time 
was 20 minutes at room temperature.  To avoid evaporation, the wells were covered.  
After the two staining, the cells were again washed with PBS twice.  Finally, 200µL of 
PBS was added to each well prior to imaging.  IN-Cell Analyzer 1000 was utilized in 
image acquisitions.  Images were obtained using 20X objective.  The quantifications of 
phospho-STAT3(Y705) were performed using IN-Cell Analyzer software.  
Statistical analysis 
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 Two-tailed t tests were used to assess the difference between two population’s 
means.  Differences were considered significant at p < 0.05.  Microsoft Excel and 
GraphPad prism software (GraphPad Software) were utilized in the analyses of cell 
viability assays and generation of bar graphs and boxplots.  The Student's t test was used 
to evaluate the statistical significance of the results.  Statistical techniques were 
performed with the R statistical package (version 2.8) for Microsoft Windows (R 
Development Core Team). 
RESULTS 
The resistant cells have higher level of phosphorylated STAT3 
 
Since STAT3 can be activated by EGFR, we wanted to determine if there were 
any changes in phosphorylation of STAT3 after treatment of Lapatinib in the sensitive 
and resistant cells.  Our western blots show that STAT3 phosphorylation is decreased in 
the sensitive cells, but was not affected significantly by Lapatinib treatment in the 
resistant cells, even after 48 hours of exposure.  See Figure 12. 
 
Figure 12.  Analysis of STAT3 phosphorylation in sensitive and resistant cells. 
Sensitive and resistant cells were treated with l µM Lapatinib for 48 hours and 
probed for phospho Y705 STAT3.  Lapatinib significantly decreased 
phosphorylation of STAT3 by 85% in the sensitive cells, while there was only a 
30% inhibition of STAT3 phosphorylation in the  resistant cells.  Quantification 
of bands was performed with ImageJ.
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The resistant cells have higher level of translocated activated STAT3 
 
 Transcriptional activation of STAT3 activity requires dimerization and 
translocation to the nucleus.  To determine if there were changes in STAT3 nuclear 
translocation, we performed IN-Cell imaging assay to determine and visualize the 
localization of STAT3 from the cytoplasm to the nucleus in both sensitive and resistant 
cell lines.  The cells were treated with Lapatinib at 1 µM for 48 hours, then imaged with 
IN-Cell Analyzer 1000.  See Figure 13A.  Quantification of phosphorylated STAT3 at 
tyrosine 705 using IN-Cell Analyzer software revealed higher level in the resistant cells, 
though levels did decrease after Lapatinib treatment.  See Figure 13B.  As illustrated by 
the box-plot, the ratio of nuclear to cytoplasmic phosphorylated STAT3 is higher in the 
resistant SkBr3-R cells than in the sensitive SkBr3 (median ratio), indicating higher level 
of STAT3 localized in the nucleus in the resistant cells, suggesting increased STAT3 
activity.  See Figure 13C.   
 
The resistant cells have higher level of transcriptional activity of STAT3 
 
To determine if the increased phosphorylation and nuclear localization of STAT3 
resulted in an increase in STAT3 transcriptional activity, we performed a transcriptional 
activation assay in which cells were transfected with a STAT3-responsive luciferase 
reporter construct Ly6E.  The results showed STAT3 transcriptional activity was 
significantly higher in the resistant cells and remained high even after treatment with 1 
µM Lapatinib for 24 hours.  See Figure 14.  In the sensitive cells, basal STAT3 activity 
was four fold lower and decreased further upon Lapatinib treatment. 
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Figure 14.  STAT3 transcriptional activity. 
The transcriptional activity of STAT3 was determined using a luciferase based 
reporter assay using the Ly6E promoter STAT3 binding response element.  STAT3 
activity was higher in resistant cells under basal conditions.   STAT3 activity in 
sensitive cells showed a 50% decrease in response to Lapatinib; however, STAT3 
activity was not inhibited by Lapatinib in the resistant cells.  
 
Targeting STAT3 with STATTIC 
 
Since we observed an increase in STAT3 phosphorylation, nuclear translocation, 
and transcriptional activity, we wanted to determine if STAT3 interference or inhibition 
can reverse the Lapatinib resistance phenotype.  We used STATTIC, which has been 
demonstrated to inhibit the function of the STAT3 SH2 domain and prevent the 
activation, dimerization, and translocation of STAT3 (110), and performed cell viability 
assays.  Our observation indicated the GI50 value for STATTIC is 0.7 µM for both cell 
lines.  See Figure 15 for dose response result.  In combination with Lapatinib in gradient 
concentrations, we found that STATTIC at 0.3 µM  significantly inhibited cell 
proliferation in the sensitive cells, whereas in the resistant cells, STATTIC 0.3 µM 
decreased Lapatinib GI50 value from 2.6 µM to 0.1 µM.  At higher concentration of 10 
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µM, STATTIC plus Lapatinib inhibited cell proliferation in both cell lines.  See Figure 
16.  
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Figure 15.  Dose response of sensitive and resistant cells to STAT3 inhibitor. 
Cell proliferation assay of sensitive and resistant cells treated with different 
concentrations of STATTIC shows both sensitive and resistant cells have GI50 0.7 µM 
in response to  STATTIC. 
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Figure 16.  Cell viability assays using combination of STATTIC and Lapatinib. 
A) STATTIC at 0.3 µM completely inhibited cell proliferation in combination with 
Lapatinib in the sensitive cells, but not in the resistant cells.  B) STATTIC at 10 µM killed 
all cells in combination with Lapatinib. 
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 CONCLUSIONS 
From the RPPA we discovered a correlation between STAT3 phosphorylation and 
Lapatinib resistance across six breast tumor cell lines, with SkBr3 Lapatinib sensitive cell 
line being a special case.  Here, the assays demonstrated 1) STAT3 phosphorylation is 
even higher in the SkBr3-R resistant cells, 2) more translocated STAT3 in the nuclei of 
the resistant cells than SkBr3, and 3) higher STAT3 activity reported by Ly6E-luciferase.  
Taken together, we have shown that STAT3 activity is further elevated in the resistant 
cells than in the sensitive cells.  Since this project began, we have provided evidence that 
Lapatinib resistance has been linked growth acceleration and apoptosis evasion and 
increased invasive index.  Interestingly, constitutive activation of STAT3 has been linked 
to those transformational phenotypes in breast carcinoma cells (94).  Plus, in a study of 
lung cancers, gene array revealed that increased STAT3 activity increases expressions of 
genes involved in cell cycle progression, apoptosis suppression, angiogenesis and 
invasion (111). 
 Thus, the question to answer now is how STAT3 activity has increased in the 
SkBr3-R resistant cells and how this change may mediate Lapatinib resistance, or at least 
how it is attributed to it.  Overactivation is thought to be either a consequence of 
dysregulation of upstream kinases or loss of endogenous inhibitors (112).  Inhibition of 
STAT3 by SOCS3 (which inhibits JAK activation) or by PIAS3 (which inhibits STAT3 
DNA binding in the nucleus) may be suppressed.  Protein tyrosine phosphatases such as 
SHP1 and SHP2 which dephosphorylates active STAT3 complexes may also be 
suppressed.  Further, in squamous cell carcinoma, breast cancer, and prostate cancer, 
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constitutive STAT3 activity is thought to be result from autocrine stimulation (Song and 
Grandis, 2000; Berclaz et al., 2001; Giri et al., 2001; Li and Shaw, 2002).  STAT3 
functions as a transcription factor for genes that encode for cytokines and growth factors, 
thus providing a mechanism for autocrine STAT activation (69, 70). 
 STAT3 overactivation may also be a result from dysregulation in other pathways 
that activate or inhibits STAT3.  Besides JAK-STAT3 pathway, STAT3 activation is also 
regulated by the MAPK pathway.  MEK kinase 1, in its inactive form inhibits STAT3 
while its active form phosphorylates S727 and Y705 via Src and JAK (113).  In another 
study, it was demonstrated that p38 MAPK activation by IL13 regulates STAT3 S727 
phosphorylation (114). 
 It was previously demonstrated that constitutively activated STAT3 frequently 
coexpresses with EGFR in gliomas and targeting STAT3 sensitizes them to gefitinib 
(115).  In our study, we targeted STAT3 using STATTIC that prevents activation and 
translocation of STAT3 to determine if the combination of STATTIC and Lapatinib will 
resensitize the resistant cells to Lapatinib.  Our preliminary results indicated the resistant 
cells are more resistant to the combination of Lapatinib and STATTIC than the sensitive 
cells, though both cell lines are equally sensitive to STATTIC.  It remains for us to 
explore further the combination of STATTIC and Lapatinib using different 
concentrations of STATTIC between 0 and 10 µM, at which toxicity is too great. 
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CHAPTER 4:  GENE EXPRESSION CHANGES IN RESISTANT CELLS 
 
INTRODUCTION 
For the past decade, the use of DNA microarrays has accelerated research in the 
biomedical field.  One of the most important applications for arrays is gene expression 
profiling where mRNA levels are measured that correspond to transcripts of tens of 
thousands of genes.  The transcription of genes is the first step in the process of protein 
synthesis.  Thus, gene expression changes can result in phenotypic differences or can be 
reflective of cellular responses to stimulation or perturbation.  In order to get a global 
perspective of the transcriptional programming that may facilitate Lapatinib resistance, 
we next performed gene array on the pair of cell lines to identify patterns of gene 
expressions that may provide clues.  Specifically, we sought to find differences in 
expression of genes involved in regulation of invasion, migration, cell cycle, survival and 
apoptosis. 
MATERIALS AND METHODS 
Transcriptional profiling 
 
 SkBr3 and SkBr3-R cells were seeded in 6-well plates (500,000 cells per well) in 
triplicates.  Next day, the cells were treated with Lapatinib at 1 µM.  Control was DMSO 
in equal volumes.  After 48 hours of treatment, the cells were lyzed and total RNA was 
extracted using Ambion mirVana miRNA Isolation Kit (Applied Biosystems) and 
amplified using Illumina Totalprep RNA Amplification Kit (Applied Biosystems), 
according to the manufacturer’s recommendations.  RNA was quantified by measuring 
absorbance at 260 nm by spectrophotometric analysis (NanoDrop).  RNA samples were 
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loaded onto HumanHT-12 Expression BeadChip (Illumina, San Diego, CA) that probes 
for 25,000 annotated genes with more than 48,000 probes.  The chips were hybridized for 
16 hours at 58Cand were scanned by UT Health Science Center Houston Microarray 
Services.  Gene array data were analyzed using BeadStudio by Illumina. 
Quantitative real-time polymerase chain reaction (RT-PCR) 
 
 Cells were lyzed and RNA was isolated by 1mL Trizol reagent (Invitrogen Life 
Technologies), following manufacturer’s recommendations.  RNA was quantified by 
measuring absorbance at 260 nm by spectrophotometric analysis (NanoDrop).  RT-PCR 
was performed by reverse transcription-PCR, triplicate samples, using Applied 
Biosystems Taqman 1-step RTPCR Reagent kit and ABI Prism 7700 Sequence Detector.  
Samples were normalized to actin housekeeping gene.   
Transfection of siRNA oligonucleotides 
 
 siRNA for PAGE2 was obtained from Dharmacon (Lafayette, CO).  Control cells 
were transfected with non-targeting (N/T) siRNA (Dharmacon, Lafayette, Colorado).  
For siRNA validation via RP-PCR, cells were seeded (600,000 per well) in triplicates for 
each condition in 6-well plates.  For cell viability assay, cells were seeded (3000 per 
well) in quintuplicates per condition per cell line.  Next day, the cells were transfected 
with PAGE2 siRNA at 20nM, 50nM, and 100nM. 
Statistical analysis 
 
 Two-tailed t tests were used to assess the difference between two population’s 
means.  Differences were considered significant at p < 0.01.  GraphPad prism software 
(GraphPad Software) and Microsoft Excel were utilized in the analyses of cell viability 
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assays.  The Student's t test was used to evaluate the statistical significance of the results.  
Statistical techniques were performed with the R statistical package (version 2.8) for 
Microsoft Windows (R Development Core Team).  Pearson’s correlation was utilized on 
the SkBr3/3R microarray data and the Gray’s 47 breast tumor cell line microarray data. 
 
RESULTS 
Resistant cells:  higher gene expressions in cell cycle regulators and DNA 
replication/repair genes 
 
 Transcriptional profiling microarray identified 394 genes (250 higher in resistant 
cells, 144 lower) in which their expressions were at least two-fold change between the 
sensitive and resistant cells when the cells were treated with Lapatinib (1 µM ) for 48 
hours.  Figure 17 shows the connected subnetworks of the 250 higher expressed genes in 
response to Lapatinib.  The graph was generated using Netwalk, created by Dr. Kakajan 
Komurov in Dr. Prahlad Ram’s laboratory. 
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Figure 17.  Gene array: higher expressed genes in resistant cells in response to 48 hour 
treatment of Lapatinib. 
 Two main subnetworks of genes populate this figure:  cell cycle regulators and 
DNA replication and repair genes.  Cell division control protein 2 homolog (CDC2), a 
central hub of this network, is required for S and M entry (116).  Other cell cycle 
regulators include Aurora kinase B (AURKB)(M phase regulator), cyclins B2 and A2 
(CCNB2, CCNA2)(CDC2 interactors) and cell division control protein 20 homolog 
(CDC20)(spindle checkpoint).  On the other hands, genes involved in DNA replication 
and repair such as Aurora kinase A (AURKA)(centrosome separation), Aurora Kinase B 
(AURKB)(chromosome passenger complex), DNA topoisomerase 2-alpha (TOP2A) and 
TOP2B (breaks and rejoins DNA), and Bloom syndrome protein (BLM)(unwinds DNA 
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during DNA replication and repair), are also at least two times in magnitude in transcript 
expressions.. 
  
Resistant cells:  lower gene expressions in cell adhesion genes and TGFb pathway genes 
  
 We also looked at two-fold minimal, transcriptional differences between the 
sensitive and resistant cells, in response to Lapatinib.  Figure 18 shows the lower gene 
expressions in the resistant cells.  Many of the claudin genes (CLDNs) were 
Figure 18.  Gene array: higher expressed genes in resistant cells in response to 48 hour 
treatment of Lapatinib. 
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downregulated during Lapatinib treatment in the resistant cells, compared to the sensitive 
cells.  These genes encode for proteins that are either components of or involved in cell 
junction and cell adhesion (117) and have been shown to be underexpressed in 
metaplastic breast cancers.  Also a major part of the network are members of the tumor 
growth factor beta (TGFβ) pathway:  activin receptor type-1 (ACVR1), TGFB2, Mothers 
against decapentaplegic homolog 3 (SMAD3), SMAD6, and FOXO3A, a proapoptotic 
gene. 
Resistant cells:  PAGE genes 
 
Gene array mRNA:  PAGE genes
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Figure 19.  Levels of PAGE genes as measured from the gene array in sensitive and 
resistant cells. 
*p<0.0001; **p<0.02 
Among the genes that were found to be most differentially expressed between the 
sensitive and resistant cells were members of the prostate-associated gene proteins 
(PAGEs):  PAGE2, PAGE2B, and PAGE5, all located on chromosome X location 
p11.21.  Alternatively known as putative G antigen family E members, the functions for 
their encoded proteins are unknown at the moment.  See Figure 19 for gene array data on 
the PAGE genes.  The mRNA levels for all three PAGE genes were found to be relatively 
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abundant (up to 20X) in the resistant cell line whereas in the sensitive cells, they were 
low.  
To determine whether a PAGE gene is essential for the resistant cells to 
proliferate in the presence of Lapatinib treatment, we first validated the gene array 
mRNA data for one of the members, PAGE2.  Using a customized set of primers 
purchased from AB Biosystems for PAGE2, we performed RT-PCR and verified the 
contrast in mRNA levels for PAGE2 between the two cell lines.  See Figure 20.  In the 
resistant cells, PAGE2 transcripts were abundant, even in the presence of Lapatinib. 
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Figure 20.  RT-PCR for PAGE2 mRNA levels. 
Resistant cells have abundant PAGE2 transcripts, 
compared to sensitive cells. 
 Next, we purchased 
PAGE2 siRNA 
oligonucleotides from 
Dharmacon and transfected 
the pair of cell lines to 
determine optimal siRNA 
concentration for 
knockdown of PAGE2 
transcript.  Concentrations 
used for testing were 20nM, 50nM and 100nM of PAGE 2 siRNA.  From the RT-PCR 
result, we determined 50nM PAGE2 siRNA concentration to be optimal for an 
approximate 80% knockdown.   See Figure 21.  Again note, in the sensitive cells, mRNA 
for PAGE2 was low.  Finally, using the 50nM siRNA concentration, we performed cell 
viability assays using Lapatinib gradient concentrations.  See Figure 22.  Comparing the 
Lapatinib dose response curves, there is no significant difference between N/T siRNA 
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and the 50nM PAGE2 siRNA conditions.   Thus, our data indicated that PAGE2 
knockdown does not increase nor decrease Lapatinib sensitivity in the resistant cells. 
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NT
20
nM
 si
RN
A
50
nM
 si
RN
A
10
0n
M 
siR
NA NT
20
nM
 si
RN
A
50
nM
 si
RN
A
10
0n
M 
siR
NA
0.00
0.25
0.50
0.75
1.00
SkBr3 SkBr3-R
Re
lat
ive
 m
RN
A 
lev
el
 
Figure 21.  PAGE2 siRNA validation using RT-PCR.  
Different concentrations of PAG2 siRNA 20, 50, 100nM were 
transfected and PAG2 transcript measured using qPCR. 50nM was 
sufficient for ~80% knockdown in the resistant cells. 
 
Figure 22.  Cell viability assay using PAGE siRNA. 
Cells were transfected with PAGE2 siRNA and treated with 
Lapatinib.  Proliferation assay showed no difference in the sensitivity 
to Lapatinib when PAGE2 is knocked down. 
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Resistant cells:  STAT3 target genes 
 
 In the gene array, we examined genes downstream of STAT3 and found several 
target genes’ expressions higher in the resistant cells after 48 hours Lapatinib treatment:  
Ly6E which promotes proliferation, BIRC5 which codes for an inhibitor of caspase 3 and 
7, HBG1 which is involved in oxygen transporter activity, TIMELESS which is required 
for S-phase progression and involved in cell survival upon DNA damage and replication 
stress, CCND1 which controls cell cycle, and CBX5 which functions as a component of 
heterochromatin during mitosis.  IRF1, which is a negative regulator of proliferation, was 
expressed lower in the resistant cells.  See Table 2 below for gene array data values.  Fold 
change (of mRNA levels) corresponds to ratio of resistant value over sensitive values for 
the Lapatinib condition. 
Table 2:  Gene array data on STAT3 target genes. 
GENE FOLD CHANGE p-value 
LY6E 1.39 0.1135
BIRC5 2.58 0.0003
HBG1 2.20 0.0719
TIMELESS 1.92 0.0219
CCND1 1.74 0.1369
CBX5 1.62 0.0548
IRF1 0.46 0.0028
 
DISCUSSION 
Utilizing transcriptional profiling, we wanted to determine what genes are 
upregulated and downregulated in response to Lapatinib in the resistant cells compared to 
the sensitive cells.  From the array data, we found many cell cycle regulating genes 
expressed higher in the resistant cells, most of which determine mitosis phase entry.  
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Additionally, genes involved with DNA replication and repair were higher expressed in 
the resistant cells.  These two networks of genes involved have overlapping genes, which 
is not surprising considering how intertwined these two cellular processes are.  
Considering Lapatinib puts cells into G1 arrest in sensitive cells, the data suggest that a 
significant subpopulation of the resistant cells were not in G1 arrest but were progressing 
through the S and G2M phases. 
On the other hand, genes whose expressions were significantly lower belong in 
networks of genes that are involved in cell junction or cell adhesion, particularly genes of 
the claudin family.  Low-claudin tumors has been identified to be aggressive, metastatic, 
chemoresistant and ”stem-cell like” (117).  We have demonstrated in our characterization 
assays that the resistant cells have higher invasive index.  Thus, the metastatic potential 
may be linked to the downregulations of the claudin genes.  Claudin-low cancers have 
been shown to have elevated CD44/CD24 ratio, which has been proposed as a breast 
cancer stem cell-like marker (118).  In our gene array, we did notice similar correlation 
between claudin-low and elevated CD44/CD24 ratio in the resistant cells, however, the 
correlation has low statistical significance in our dataset. 
Several target genes of STAT3 were discovered to be expressed higher in the 
resistant cells compared to the sensitive cells:  Ly6E, BIRC5, HBG1, TIMELESS, and 
CCND1, and CBX5.  With the exception of HBG1, these genes code for proteins that 
promotes proliferation or survival or cell cycle progression.  CBX5 was recently 
discovered by Gray’s lab to be upgregulated in Lapatinib resistant cells in vivo.  IRF1 is 
also a target gene of STAT3 that is a negative regulator of proliferation, and in the array 
it is expressed significantly lower in the resistant cells.   
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Our gene array identified a family of genes that was abundantly present in the resistant 
cells but not in the sensitive cells.  These PAGE genes were interesting in that their 
products and functions are unknown at this time.  However, their sequences are similar to 
the G antigen family members (GAGEs) that are expressed abundantly in germline cells, 
associated with high proliferation, and may have antiapoptotic functions (119).  
Nevertheless, our cell viability assays using PAGE2 siRNA showed that knockdown of 
the gene did not reverse the Lapatinib resistance phenotype.  It remains for us to test 
RNA interference for the other PAGE family members.  However, given our preliminary 
results from PAGE2 experiments, it is likely that the PAGE2 is a passenger rather than 
driver of Lapatinib resistance. 
So how did our array compared to array done by others in similar conditions?  In 
another study, gene array was performed on the pair of Lapatinib-sensitive cell lines 
BT474 and SkBr3 (120).  Consistent with their array with 12 hour Lapatinib treatment, 
we discovered in our array decreased transcripts for AKT1, IRAK1, and CCND1 and 
increased FOXO3A in the sensitive SkBr3 cells in response to 48 hours treatment of 
Lapatinib at the same concentration (1 µM).  Interestingly, in our resistant SkBr3-R cells, 
AKT and IRAK1 did not decrease, CCND1 actually increased and FOXO3A only 
increased slightly.  Previously, in a BT474 and a Lapatinib resistant clonal cell line 
treated with Lapatinib, FOXO3A was showed to be upregulated which resulted in a 
switch to ER signaling, survival factors regulation, and the cell line’s ability to evade 
apoptosis (38).  In our SkBr3-R Lapatinib resistant cell line, FOXO3A is one of the 
tumor suppressor genes shown to be expressed lower in the resistant cells than in the 
sensitive cells, see Figure 18 (previous Netwalk graph).  Thus, ER signaling does not 
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appear to be an alternative pathway for pro-survival for the SkBr3-R cells, though BIRC5 
(which codes for survivin) is significantly expressed, similar to Xia’s observation.  
Another argument for the hypothesis that ER signaling not active in the SkBr3-R cells is 
that BT474 is ER+ while SkBr3 is ER-.  The resistant SkBr3-R cells is also ER- based on 
the gene array data, though we have not determine ER protein expression experimentally. 
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CHAPTER 5 SUMMARY AND FUTURE DIRECTION 
 
 
 In human breast carcinomas, EGFR and ErbB2 are often overexpressed and 
associated with poor patient outcome.  Thus, pharmacological agents that target these 
receptors provide attractive therapeutics.  Lapatinib is one of the latest drugs approved by 
FDA for the treatment of breast cancer patients.  However, acquired Lapatinib resistance 
has been recognized as a major concern today.  Since mechanisms of drug sensitivity and 
acquired drug resistance were not fully elucidated, the purpose of this study was to 
understand acquired resistance to Lapatinib in breast cancer cells. 
 To understand acquired Lapatinib resistance, we established a system of isogenic 
cell lines in which one cell line is sensitive to Lapatinib (SkBr3) and the other resistant to 
it (SkBr3-R).  The resistant cell line was established by gradual increase of 
concentrations of the drug over a span of 12 months.  Once its Lapatinib resistance was 
verified, we began experimentation to determine mechanisms that may contribute 
resistance. 
In our characterizations of the Lapatinib sensitive SkBr3 and resistant SkBr3-R 
cell lines, we first examined the usual suspects for drug resistance.  Western blots 
indicated no significant difference in receptor expression or phosphorylation for ErbB1, 
ErbB2, ErbB3, and ErbB4.  Since mutations have been identified to confer resistance in 
previous studies of other anti-ErbB drugs, we sequenced ErbB receptors of the resistant 
SkBr3-R cells for exons that have been reported to contain mutations in different tumor 
types.  However, we did not find any mutations occurred in either cell line for those 
exons.  It remains for us to sequence the remaining exons for these ErbB receptors, 
particularly those exons in the kinase domains.  Other characterization assays performed 
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included wound healing and Matrigel; they provided evidence that the resistant cells have 
similar wound healing capacity, but higher invasive potential.   
Cell cycle and apoptosis assays identified apoptosis evasion and cell cycle 
progression as attributes of Lapatinib acquired resistance.  From the cell cycle analyses, 
we demonstrated that both sensitive and resistant cells initially underwent G1 arrest upon 
Lapatinib treatment.  However, as the days passed, the resistant cell population 
eventually decreased its G1 phase population, indicating progression of cell cycle.  That 
observation was further supported in our gene array where expressions of many cell cycle 
dependent genes that assist in cell cycle progression were higher in the resistant cells.  In 
addition, several pro-apoptotic genes were expressed higher in the sensitive cells whereas 
anti-apoptotic genes were expressed higher in the resistant cells. 
Because of STAT3 overactivation has been linked to abnormal growth and 
survival, invasion and metastasis in cancer and its involvement in other anti-ErbB drug 
resistance, we investigated into its role in Lapatinib resistance.  From our western blots, 
IN-Cell images, and luciferase reporter assay, we showed that the resistant cells have 
elevated STAT3 activity.  Complementary, the gene array showed increased STAT3 
transcripts upon Lapatinib treatment, though for the sensitive cells it is not clear why 
transcript level increased despite inhibition of STAT3 phosphorylation in the western 
blots.  Nevertheless, many STAT3 target genes’ transcript levels were higher in the 
resistant cells, and their expression may contribute to Lapatinib resistance through 
promotion of cell cycle progression and cell survival. 
We targeted STAT3 activity using STATTIC, an inhibitor of its activation.  
Preliminary results showed the resistant cell line to be more resistant to the combination 
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of STATTIC and Lapatinib despite same STATTIC GI50 value for both sensitive and 
resistant cell lines.  It remains to determine if STAT3 inhibition in combination with 
Lapatinib will inhibit proliferation in the resistant cells. 
 In the gene array, we discovered a family of genes that provided the highest level 
of contrast in terms of mRNA levels between the resistant and sensitive cell lines.  Little 
is known about this PAGE family, though information on a related family GAGE 
suggests PAGE proteins may have antiapoptotic functions and may be exclusive to 
germline cells.  We performed cell viability assay using siRNA against one of the 
members (PAGE2) to determine its role in Lapatinib resistance, but did not confirm it as 
a driving force in resistance.   
From the gene array, we also identified a family of genes, the claudins, that were 
lower expressed in the resistant cells in response to Lapatinib treatment.  These genes 
code for proteins that are essential for cell junction and cell adhesion.  The results suggest 
that the increase in metastatic potential may be contributed by the downregulation of 
these claudin genes.  The clinical significance of these genes is that they are lowly 
expressed in metaplastic breast cancers with metastatic and chemoresistant characteristics 
and are stem-cell like.  
Altogether, this study has identified genes and proteins implicated in several 
cellular processes that are involved in Lapatinib resistance, some of which may be 
contributors to the resistance:  STAT3 and its target genes, PAGE genes, claudin genes, 
cell cycle regulatory genes, TGFb pathway genes.  Further research is required in 
determining if targeting them will resensitize resistant cells to Lapatinib. 
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APPENDIX A 
 
Receptor  Exon 
Primer 
type  Tm 2ndary Sequence
product 
size
EGFR  18  forward  59.4 weak TGTAGAGAAGGCGTACATTTG  457
EGFR  18  reverse  58.2 none TTTCCTCTCAATAACTTGGG 
EGFR  19  forward  72.6 strong GCAATATCAGCCTTAGGTGCGGCTC  357
EGFR  19  reverse  61.4 weak CATAGAAAGTGAACATTTAGGATGTG 
EGFR  20  forward  66.7 none ATTCATGCGTCTTCACCTGGA  367
EGFR  20  reverse  64.0 moderate ATGGCAAACTCTTGCTATCCC 
EGFR  21  forward  63.1 none ACATGACCCTGAATCGGAT  308
EGFR  21  reverse  55.9 none ACAATACAGCTAGTGGGAAG 
EGFR  22  forward  56.7 none CACTCGTAATTAGGTCCAGA  255
EGFR  22  reverse  57.6 very weak TGCATGTCAGAGGATATAATG 
EGFR  25  forward  66.2 weak GACCCCTGCTCCTATAGCCAA  331
EGFR  25  reverse  55.1 none CACTAGATGGTTATTTTCCC 
ErbB2  19  forward  60.4 weak GGATGTTTGGAGGACAAGTAA  275
ErbB2  19  reverse  64.6 none AACCCCAATGAAGAGAGACCA 
ErbB2  20  forward  65.7 none TGGTTTGTGATGGTTGGGAG  346
ErbB2  20  reverse  64.1 none CAGCAAGAGTCCCCATCCTA 
ErbB2  21  forward  71.2 weak GGACTCTTGCTGGGCATGTGG  298
ErbB2  21  reverse  65.9 weak CCACTCAGAGTTCTCCCATGG 
ErbB2  22  forward  65.2 weak GTGGAGTGGTGTCTAGCCCAT  244
ErbB2  22  reverse  64.5 none TAATTCTCCCCATCCCAGCT 
ErbB3  20  forward  63.8 none TATGCCGCTAGGAGAGAGGA  534
ErbB3  20  reverse  68.5 very weak TGCCGCTCACATGCTCTGT 
EGFR  18  forward  64.1 moderate GGCACTGCTTTCCAGCAT  249
EGFR  18  reverse  67.5 none TCCCCACCAGACCATGAGAG 
EGFR  19  forward  64.6 moderate CATGTGGCACCATCTCACA  230
EGFR  19  reverse  64.2 none CAGCTGCCAGACATGAGAAA 
ErbB3  20  forward  63.5 weak TGTGCACATGCTGAGTGTATG  299
ErbB3  20  reverse  64.2 very weak CCCCCAGACAAGCAGTTCT 
 
Primers used to amplified exons in EGFR, ErbB2, and ErbB3.  Sequences used for primer 
designing program Primer3 were extracted from genomic intron sequences 100 base pairs 
before and after each exon sequence. 
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